Meeting
2020 ASCO-SITC Clinical Immuno-Oncology Symposium
Deleterious alterations of DNA damage response and repair (DDR) genes in association with clinical benefit to programmed cell death protein-1 (PD-1)/PD ligand 1 (PD-L1)-based therapy in esophageal squamous cell carcinoma (ESCC).
Authors
Jhe-Cyuan Guo
National Taiwan University Cancer Center, Taipei City, Taiwan
Jhe-Cyuan Guo, Chia-Chi Lin, Ta-Chen Huang, Chun-Jung Chang, Hung-Yang Kuo, Chih-Hung Hsu
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Poster Session A
Track
Breast and Gynecologic Cancers,Developmental Therapeutics,Genitourinary Cancer,Head and Neck Cancer,Lung Cancer,Melanoma/Skin Cancers,Gastrointestinal Cancer,Combination Studies,Implications for Patients and Society,Miscellaneous Cancers,Hematologic Malignancies
Sub Track
Biomarkers and Inflammatory Signatures
Citation
J Clin Oncol 38, 2020 (suppl 5; abstr 28)
Abstract #
28
Poster Bd #
C5
Abstract Disclosures
Similar Posters
Poster
2019 Gastrointestinal Cancers Symposium
Molecular comparison of primary colorectal cancer (pCRC) with peritoneal metastases (PM).
First Author: Matthew K Stein
Poster
2023 ASCO Genitourinary Cancers Symposium
Association of biomarkers and outcomes in patients (pts) with metastatic urothelial carcinoma (mUC) treated with immune checkpoint inhibitors (ICIs).
First Author: Kevin R Reyes
Poster
2022 ASCO Annual Meeting
LAG3 transcriptomic expression correlates with high levels of PD-1, PD-L1, PD-L2, and CTLA-4 checkpoints and with high tumor mutational burden across cancers.
First Author: Jacob J. Adashek
Poster
2022 ASCO Annual Meeting
Circulating tumor DNA (ctDNA) in predicting residual disease after neoadjuvant chemoradiotherapy (nCRT) for esophageal squamous cell carcinoma (ESCC).
First Author: Zhichao Liu